Who is sponsoring NCT03098550?

NCT03098550 is sponsored by Bristol-Myers Squibb.

What condition does NCT03098550 study?

NCT03098550 studies Advanced Cancer.

What drugs are being tested in NCT03098550?

Interventions: Nivolumab, Daratumumab.

What is the status of NCT03098550?

NCT03098550 is currently COMPLETED.

Last reviewed 2021-07-23 · How we verify

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

NCT03098550 PHASE1, PHASE2 COMPLETED Results posted

The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	105
Start date	Thu Jun 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Advanced Cancer

Interventions

Nivolumab
Daratumumab

Countries

France, Italy, Germany, Canada, Puerto Rico, Australia, Switzerland, United States, Spain